Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TRIMETAZIDINE DIHYDROCHLORIDE- REFERENCE SPECTRUM (N/A)

TRIMETAZIDINE DIHYDROCHLORIDE- REFERENCE SPECTRUM (N/A)

NA

DISCOVER
TRIMETAZIDINE FOR SYSTEM SUITABILITY CRS (50 MG)

TRIMETAZIDINE FOR SYSTEM SUITABILITY CRS (50 MG)

13171-25-0

DISCOVER
DIOSMIN CRS (70 MG)

DIOSMIN CRS (70 MG)

520-27-4

DISCOVER
DIOSMIN FOR SYSTEM SUITABILITY CRS (15 MG)

DIOSMIN FOR SYSTEM SUITABILITY CRS (15 MG)

520-27-4

DISCOVER
MESTEROLONE  IMPURITY A CRS (40 MG)

MESTEROLONE IMPURITY A CRS (40 MG)

604-26-2

DISCOVER
MESTEROLONE  CRS (120 MG)

MESTEROLONE CRS (120 MG)

1424-00-6

DISCOVER
PENTOXYVERINE IMPURITY A CRS (15 MG)

PENTOXYVERINE IMPURITY A CRS (15 MG)

77-55-4

DISCOVER
PENTOXYVERINE IMPURITY B CRS (15 MG)

PENTOXYVERINE IMPURITY B CRS (15 MG)

77-22-5

DISCOVER
ORPHENADRINE HYDROCHLORIDE CRS (100 MG)

ORPHENADRINE HYDROCHLORIDE CRS (100 MG)

341-69-5

DISCOVER
ORPHENADRINE CITRATE CRS (100MG)

ORPHENADRINE CITRATE CRS (100MG)

4682-36-4

DISCOVER
ORPHENADRINE IMPURITY E CRS (60 MG)

ORPHENADRINE IMPURITY E CRS (60 MG)

NA

DISCOVER
CARVEDILOL IMPURITY C CRS (15MG)

CARVEDILOL IMPURITY C CRS (15MG)

72955-94-3

DISCOVER